Sex-related differences in platelet aggregation in native whole blood

Zwierzina, Wolf-Dieter; Kúnz, F; Kogelnig, R.; Herold, Manfred

doi:10.1016/0049-3848(87)90412-9

Cited by 33 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several experiments have shown gender differences in the inhibitory effect of aspirin on platelet aggregation, and most of them concluded that the inhibitory effect of aspirin was greater in male than in female subjects [9, 10, 11]. These experimental data also support clinical data which showed that aspirin reduced the risk of vascular events more in male than in female subjects.…”

Section: Discussionsupporting

confidence: 78%

The Antiplatelet Aggregation Effects of Aspirin Suppositories

et al. 2003

View full text Add to dashboard Cite

To confirm that aspirin suppositories are an effective treatment for acute ischemic stroke, we examined the suppressive effects of 200-mg aspirin suppositories on platelet aggregation. Aspirin suppositories suppressed platelet aggregation induced by ADP or collagen, and the suppression continued for 24 h. There was no significant difference in suppression of platelet aggregation between aspirin administered by suppository and orally given aspirin. These results suggest that aspirin suppositories are a useful treatment for acute ischemic stroke.

show abstract

Section: Discussionsupporting

confidence: 78%

The Antiplatelet Aggregation Effects of Aspirin Suppositories

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The explanation for these sex differences remains uncertain but it has been suggested lower haematocrit values for women may account for this observation (Kelton et al, 1980). However, other substantive studies and our own data have failed to demonstrate such an association (Coppe et al, 1981;Zwierzina et al, 1987). It has also been demonstrated that androgens and/or other sex-linked (hormonal) factors, may underlie the differences in platelet aggregability (Zwierzina et al, 1987).…”

Section: Discussionmentioning

confidence: 72%

“…However, other substantive studies and our own data have failed to demonstrate such an association (Coppe et al, 1981;Zwierzina et al, 1987). It has also been demonstrated that androgens and/or other sex-linked (hormonal) factors, may underlie the differences in platelet aggregability (Zwierzina et al, 1987). Of interest, after aspirin ingestion, gender-associated effects were restricted to platelet responses to PAF alone, with aspirin having a greater effect in females than in males.…”

Section: Discussionmentioning

confidence: 78%

The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid.

Taylor

Misso

Stewart

et al. 1992

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. The effect of increasing doses of orally administered aspirin (30‐ 900 mg) on platelet aggregation and ATP release induced by arachidonic acid (AA), collagen and platelet activating factor (PAF) was assessed in 12 normal volunteers. 2. Aspirin ingestion was associated with a significant increase in EC50 for AA (P less than 0.0001) and collagen (P less than 0.0001) but not for PAF (P greater than 0.495) although the normal biphasic aggregation response for the latter was abolished. Maximum ATP release was reduced by aspirin for all three agonists. 3. The mean maximum degrees of inhibition of platelet aggregation induced by aspirin for AA, collagen and PAF were 100%, 48% and 21% of baseline, respectively. The corresponding mean maximum inhibition of ATP release was 100%, 63% and 57%. The minimum cumulative doses of aspirin producing these effects were 240, 240 and 90 mg for AA, collagen and PAF respectively. For collagen alone, there was a significant decrease in the degree of inhibition of aggregation between the last dose on day 1 (150 mg) and the baseline measurement on day 2. 4. Platelets from female subjects were more sensitive to collagen (P less than 0.05) and AA (P less than 0.01) stimulation compared with males. However, prior to aspirin ingestion, PAF produced a greater maximum response in platelets from females (P less than 0.02) while following aspirin ingestion PAF‐induced activation was inhibited to a greater degree in females (P less than 0.02). 5. These results indicate that collagen‐ and PAF‐induced platelet activation are only partially dependent on cyclo‐oxygenase and for PAF this seems related only to the second phase of aggregation.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…A number of ex vivo functional assays has showed that women possess an increased platelet reactivity compared to their male counterparts, in terms of platelet-to-platelet aggregation [11][12][13][14], adhesiveness to fibrinogen [15][16][17][18][19][20] and interaction with leukocytes to form heterotypic aggregates [21]. In particular, some evidences have shown that platelet aggregation is enhanced in women.…”

Section: Gender Differences In Platelet Function and Clinical Implicamentioning

confidence: 99%

Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment

Giosia

Passacquale

Petrarca

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

Cardiovascular disease (CVD) represents the leading cause of death worldwide, and equally affects both sexes although women develop disease at an older age than men. A number of clinical evidence has identified the female sex as an independent factor for poor prognosis, with the rate of mortality and disability following an acute cardiovascular (CV) event being higher in women than men. It has been argued that the different level of platelet reactivity between sexes may account for a different responsiveness to anti-platelet therapy, with consequent important implications on clinical outcomes. However, conclusive evidence supporting the concept of a gender-dependent effectiveness of platelet inhibitors are lacking. On the contrary, sex-related dissimilarities have been evidenced in cardiovascular patients in terms of age of presentation, comorbidities such as obesity, diabetes and renal disease, and a different pharmacological approach to and effectiveness in controlling classical cardiovascular risk factors such as hypertension, glucose profile and lipid dysmetabolism. All these factors could place women at an increased level of cardiovascular risk compared to men, and may concur to an enhanced pro-thrombogenic profile. The purpose of this manuscript is to provide an overview of gender-related differences in cardiovascular treatment, in order to highlight the need to improve the pharmacological prophylaxis adopted in women through a more accurate evaluation of the overall cardiovascular risk profile with consequent establishment of a more effective and targeted anti-thrombotic strategy which is not limited to the use of antiplatelet agents.

show abstract

Sex-related differences in platelet aggregation in native whole blood

Cited by 33 publications

References 33 publications

The Antiplatelet Aggregation Effects of Aspirin Suppositories

The Antiplatelet Aggregation Effects of Aspirin Suppositories

The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid.

Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment

Contact Info

Product

Resources

About